Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
Crossref DOI link: https://doi.org/10.1007/s00198-015-3179-x
Published Online: 2015-06-12
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ferrari, S.
Adachi, J. D.
Lippuner, K.
Zapalowski, C.
Miller, P. D.
Reginster, J.-Y.
Törring, O.
Kendler, D. L.
Daizadeh, N. S.
Wang, A.
O’Malley, C. D.
Wagman, R. B.
Libanati, C.
Lewiecki, E. M.
License valid from 2015-06-12